Skip to content

Swiftpharma

Active
Private limited companyfounded 2022active for 4 yearsThor Park 8027, 3600 Genk, BelgiumKBO/BCE: BE 0781.598.284

From the official registers: KBO 3 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

The computed 12-month bankruptcy probability of Swiftpharma is 2.0% (moderate). The annual accounts of Swiftpharma for financial year 2025 show a net loss of 68% of the equity at the start of that year. The 2025 annual accounts show equity of €834,755 and a net result of -€1.8m. Equity is growing by about 46% per year across the filed financial years. Its solvency ranks better than 24% of 9,829 sector peers (NACE 46, financial year 2025). The company has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals.

Risk analysisFollow ReportCompare
SwiftpharmaActiveChecked score 53/100
Risk analysis ReportCompare

Directors

Directors
3 directors, last change in 2026

Board 3

HofMan BV
Director · since 01-12-2024 · Legal entity · permanent representative: Jeroen Hofenk · in the 2025 annual accounts, filed on 27-04-2026
Current
SCHIPPER Daniel Bernard
Director · appointed in the act of 23-09-2026
Current
TOUWEN Jasper Lode
Director · appointed in the act of 23-09-2026
Current

Permanent representatives 1

Jeroen Hofenk
Permanent representative · appointed in the act of 10-01-2025 · for HofMan BV
Current
Office holders in the KBO →

Mandate history

9 people, 3 in office
Show
  • Board
  • began earlier
Mandates per person, with start and end dates
Name Functions and periods
HofMan BV
  • Director, from 01-12-2024 to date
SCHIPPER Daniel Bernard
  • Director, appointed in the act of 23-09-2026, still in office
TOUWEN Jasper Lode
  • Director, appointed in the act of 23-09-2026, still in office
PERRENET Raymond Roger
  • Director, appointed in the act of 01-10-2024, until 23-09-2026
Bart Goddyn
  • Class A director, appointed in the act of 08-08-2025, until 08-10-2025
JVHealth
  • Class A director, until 08-08-2025
ASTERION RESEARCH & DEVELOPMENT
  • Director, until 01-12-2024
BV CHRISTIAN DEPREZ CONSULTING
  • Director, until 20-09-2023
Christian Deprez
  • Manager, until 23-08-2023
See the board, name and registered office on a given date →

How the board is organised

Who represents it, and how

Who signsWho may bind the company towards others, for example by signing a contract.
Two directors jointly
deed of 23-09-2026
Board ruleHow the board is made up, meets and takes decisions.
“Bepaalde of onbepaalde duur, raad van bestuur”
“Vaste vertegenwoordiger voor rechtspersoon-bestuurder, hoofdelijk aansprakelijk”
“Voorzitter of bij diens afwezigheid het lid van het college dat bij gewone meerderheid is aangeduid, college van bestuurders”
“Bestuursorgaan bepaalt of alleen of gezamenlijk optreden, overeenkomstig de bepalingen van de Aandeelhoudersovereenkomst”
1 more provision on this in the deed
deed of 23-09-2026 (in Dutch)
Power of attorneyA special mandate allowing someone to perform one or more acts on the company's behalf.
“Philippe Van den Broecke”
“Victor Burki”
“Lies de Mulder”
1 more provision on this in the deed
deed of 10-01-2025 (in Dutch)

Oversight and winding up

Dissolution ruleWhen and by whom the company can be dissolved.
One provision in the deed
Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
“Bij ontbinding bestuurders in functie aangewezen als vereffenaars krachtens statuten indien geen andere vereffenaar benoemd, vereffenaars”
1 more provision on this in the deed

deed of 01-10-2024 (in Dutch)

Owners and capital

Owners

1 owner

Chain of control

  1. ASTERION RESEARCH & DEVELOPMENT 52.8%
  2. Swiftpharma

Owners 1

Capital and shareholders

Capital over the years
  1. 23-09-2026 Capital increase of €1,700,000 · 69,444 new shares · in cash
  2. 23-09-2026 Capital increase of €1,521,764 · 62,164 new shares · in kind
  3. 23-09-2026 Capital increase of €1,700,000 · 69,444 new shares · in cash
  4. 23-09-2026 Capital increase of €1,521,764 · 62,164 new shares · in kind
  5. 01-10-2024 Capital increase of €4,410,000 · 1,667 new shares · in cash

Shares according to the articles of association

Profit allocationHow profit is distributed; a BV may only pay out after a balance-sheet and liquidity test.
“Hun Pro Rata Aandelenbezit, in voorkomend geval verminderd met het overgedragen verlies of vermeerderd met het overgedragen winst”
Other provisionsRules from the articles on subjects other than the board, the shares, the purpose and the meetings.
Liquidation distribution: “De goederen die nog in natura voorhanden zijn worden op dezelfde wijze verdeeld, na aanzuivering van alle schulden, lasten en kosten van de…”
Other provision: “Mag alleen beslissen over de voorstellen die zijn opgenomen in de agenda, agenda”
Other provision: “Totaal aantal uitgegeven aandelen aanwezig of vertegenwoordigd, quorum”
Other provision: “Meerderheid van stemmen, ongeacht het aantal aandelen dat op de algemene vergadering aanwezig of vertegenwoordigd is”
Liquidation distribution: “Goederen die nog in natura voorhanden zijn op dezelfde wijze verdeeld, na aanzuivering van alle schulden, lasten en kosten van de…”
8 more provisions in the deed, see the deed of 23-09-2026

Articles of association, deed of 23-09-2026 (in Dutch)

We would like to set cookies. That happens only with your consent. What we measure